Analysts are piling on the praise for Vertex Pharmaceuticals, reaffirming bullish ratings even as the stock slightly fumbles ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Google Cloud’s Vertex AI, a machine learning (ML) platform, is receiving significant updates. Vertex AI is a tool for enterprise AI development. Unlike consumer-facing AI like Gemini or ChatGPT ...

BOSTON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets ...